The news highlights the urgent need for more consistent, wide scale detection of the disease at an early stage

Vancouver, British Columbia--(Newsfile Corp. - May 9, 2023) -Cognetivity Neurosciences Ltd.(CSE:CGN) (OTCQB:CGNSF) (FSE: 1UB)("the Company" or "Cognetivity") is pleased to note Eli Lilly & Co.'s results for its experimental drug for Alzheimer's disease, which demonstrated slowing the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. The drug, donanemab, slowed the disease by 35% over a year and a half in a trial of 1,182 patients with early-stage Alzheimer...